Related Experiment Video

Updated: Jun 16, 2026

Preparation of Naringenin Solution for In Vivo Application
08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

Nobiletin improves hyperglycemia and insulin resistance in obese diabetic ob/ob mice

Young-Sil Lee1, Byung-Yoon Cha, Kiyoto Saito

  • 1Research Institute for Biological Functions, Chubu University, Kasugai, Aichi, Japan.

Biochemical Pharmacology
|February 11, 2010
PubMed

Insights

Nobiletin, a citrus flavonoid, enhances insulin sensitivity and improves glucose control in obese diabetic mice. It achieves this by modulating adipokine expression and glucose transporter levels in adipose tissue and muscle.

Area of Science:

  • Pharmacology
  • Metabolic Diseases
  • Nutraceuticals

Background:

  • Nobiletin, a polymethoxylated flavone from citrus fruits, possesses known anti-inflammatory, antitumor, and neuroprotective effects.
  • Obesity and diabetes are significant global health concerns characterized by insulin resistance and hyperglycemia.
  • Understanding natural compounds' effects on metabolic health is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To investigate the impact of nobiletin on insulin sensitivity in obese diabetic (ob/ob) mice.
  • To elucidate the underlying molecular mechanisms by which nobiletin exerts its effects.

Main Methods:

  • Obese diabetic ob/ob mice were administered nobiletin (200 mg/kg) for five weeks.
  • Evaluated plasma glucose, insulin resistance (homeostasis model assessment index), and glucose tolerance (oral glucose tolerance test).
  • Analyzed gene and protein expression of adipokines, peroxisome proliferator-activated receptor gamma (PPAR-γ), and glucose transporters (Glut1, Glut4) in white adipose tissue (WAT) and muscle.

Main Results:

  • Nobiletin treatment significantly reduced plasma glucose levels and improved insulin resistance.
  • Oral glucose tolerance tests showed enhanced glucose tolerance in nobiletin-treated mice.
  • Nobiletin modulated inflammatory adipokines (IL-6, MCP-1) and increased adiponectin, PPAR-γ, and glucose transporter (Glut1, Glut4) expression in WAT and muscle.

Conclusions:

  • Nobiletin effectively improves hyperglycemia and insulin resistance in a mouse model of obesity and diabetes.
  • The observed benefits are attributed to nobiletin's ability to regulate adipokine expression in WAT.
  • Nobiletin enhances glucose uptake by modulating Glut1 and Glut4 expression in adipose tissue and muscle.

More Related Videos

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice06:16

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...